Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States

被引：3
|
作者：
Peng, Siyang [1 ]
Tafazzoli, Ali [1 ]
Dorman, Emily [1 ]
Rosenblatt, Lisa [2 ]
Villasis-Keever, Angelina [3 ]
Sorensen, Sonja [1 ]
机构：
[1] Evidera, Modeling & Simulat, Bethesda, MD USA
[2] Bristol Myers Squibb Co, Hlth Econ & Outcomes Res, Plainsboro, NJ USA
[3] Bristol Myers Squibb Co, HIV Med Strategy, Plainsboro, NJ USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2014年 / 17卷
关键词：
D O I：
10.7448/IAS.17.4.19605
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P073
引用
收藏
页码：78 / 78
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
    Peng, Siyang
    Tafazzoli, Ali
    Dorman, Emily
    Rosenblatt, Lisa
    Villasis-Keever, Angelina
    Sorensen, Sonja
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (10) : 763 - 776
  • [2] The ADVANCE trial: Phase 3, randomized comparison of TAF/FTC/DTG, TDF/FTC/DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection
    Venter, W. F.
    Moorhouse, M.
    Sokhela, S.
    Fairlee, L.
    Mashabane, N.
    Masenya, M.
    Qavi, A.
    Clayden, P.
    Abrams, E. J.
    Simmons, B.
    Hill, A.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 103 - 104
  • [3] The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC plus DTG, TDF/FTC plus DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection
    Venter, F.
    Sokhela, S.
    Fairlie, L.
    Serenata, C.
    Mashabane, N.
    Masenya, M.
    Qavi, A.
    McCann, K.
    Simmons, B.
    Clayden, P.
    Hill, A.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 185 - 185
  • [4] Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load
    Flandre, P.
    Pugliese, P.
    Allavena, C.
    Katlama, C.
    Cotte, L.
    Cheret, A.
    Cabie, A.
    Rey, D.
    Chirouze, C.
    Bani-Sadr, F.
    Cuzin, L.
    [J]. HIV MEDICINE, 2016, 17 (05) : 380 - 384
  • [5] COST-EFFECTIVENESS OF EFAVIRENZ VERSUS RILPIVIRINE IN HIV PATIENTS INITIATING FIRST-LINE TREATMENT IN THE UNITED STATES
    Bonafede, M.
    Juday, T.
    Lenhart, G.
    Pan, K.
    Hebden, T.
    Correll, T.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A241 - A241
  • [6] COST-EFFECTIVENESS ANALYSIS OF DOLUTEGRAVIR/ LAMIVUDINE (DTG/3TC) VERSUS ELVITEGRAVIR/ COBICISTAT/TENOFOVIR ALAFENAMIDE/EMTRICITABINE (EVG/C/TAF/FTC) FOR HIV-1 INFECTION MANAGEMENT IN TREATMENT-EXPERIENCED PATIENTS IN CHINA
    Fan, L.
    Tang, Z.
    Jacob, I
    Anderson, S. J.
    Kabra, M.
    Turner, M.
    Tewary, A.
    Harrison, C.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S82 - S82
  • [7] 48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
    Y Yazdanpanah
    M-A Khuong-Josses
    L Hocqueloux
    G Pialoux
    J Durant
    B Wynne
    C Granier
    P Tebas
    K Pappa
    S Min
    [J]. BMC Infectious Diseases, 14 (Suppl 2)
  • [8] Real-world persistence of E/C/F/TAF versus DTG+ABC/3TC regimens for treatment of HIV in a large Spanish cohort: VACH
    Teira, R.
    Romero, A.
    Roca, B.
    Munoz-Sanchez, M.
    Sepulveda, M.
    Puig, T.
    Espinosa, N.
    Merino, M.
    Geijo, P.
    Castano, M.
    Estrada, V.
    Ribera, E.
    Domingo, P.
    De la Fuente, B.
    Montero, M.
    Galindo, M.
    Peraire, J.
    Martinez, E.
    Lozano, F.
    Terron, A.
    Garcia, J.
    Deig, E.
    Munoz-Sanz, A.
    Gutierrez, M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [9] COST-EFFECTIVENESS OF EFAVIRENZ COMPARED WITH GENERIC NEVIRAPINE IN HIV PATIENTS INITIATING FIRST-LINE TREATMENT IN THE UNITED STATES
    Bonafede, M. M.
    Juday, T.
    Farr, A.
    Lenhart, G. M.
    Hebden, T.
    Correll, T.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A92 - A92
  • [10] COST-EFFECTIVENESS OF CETUXIMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN THE UNITED STATES
    Ortendahl, J. D.
    Bentley, T. G.
    Anene, A. M.
    Purdum, A. G.
    Bolinder, B.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A86 - A86
12345